MTHFD2L inhibitors would be a class of chemical compounds designed to inhibit the activity of the enzyme MTHFD2L (methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2-like). This enzyme is part of the family of enzymes involved in the folate metabolism pathway, which plays a critical role in the synthesis of purines and thymidylate, the building blocks of DNA, and also in the metabolism of amino acids. The "2-like" indicates that MTHFD2L shares some similarities with the MTHFD2 enzyme, suggesting that it might have overlapping or distinct functions in cellular metabolism. Inhibition of such an enzyme would involve blocking its active site or interfering with its catalytic mechanism, which is essential for its role in the folate cycle.
The discovery and characterization of MTHFD2L inhibitors would commence with a comprehensive understanding of the enzyme's structure, its active site, and the mechanism by which it catalyzes reactions in folate metabolism. Determining the three-dimensional structure of MTHFD2L would be a pivotal step, providing insights into potential binding pockets and regions of the enzyme critical for its function. Advanced methods such as X-ray crystallography, cryo-electron microscopy, or NMR spectroscopy would be employed to gain this structural information. Additionally, computational methods would be instrumental in modeling the interactions between potential inhibitors and the enzyme, allowing for the rational design of molecules that could effectively bind to and inhibit MTHFD2L.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate is a folate analog that inhibits dihydrofolate reductase, potentially reducing the availability of substrates for MTHFD2L. | ||||||
N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid | 137281-23-3 | sc-479733 | 250 mg | $330.00 | 1 | |
Pemetrexed inhibits several enzymes involved in folate metabolism and could indirectly affect MTHFD2L expression. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
5-Fluorouracil is metabolized to products that inhibit thymidylate synthase, and could alter folate metabolism and MTHFD2L function. | ||||||
Raltitrexed | 112887-68-0 | sc-219933 | 10 mg | $146.00 | ||
Raltitrexed is a thymidylate synthase inhibitor that may disrupt folate metabolism and thereby affect MTHFD2L expression. | ||||||
Pyrimethamine | 58-14-0 | sc-208190 sc-208190A sc-208190B | 1 g 5 g 25 g | $80.00 $238.00 $825.00 | 5 | |
Pyrimethamine is an antiparasitic drug that inhibits dihydrofolate reductase, which may influence MTHFD2L activity. | ||||||
Trimethoprim | 738-70-5 | sc-203302 sc-203302A sc-203302B sc-203302C sc-203302D | 5 g 25 g 250 g 1 kg 5 kg | $67.00 $161.00 $255.00 $721.00 $3401.00 | 4 | |
Trimethoprim is an antibiotic that inhibits bacterial dihydrofolate reductase, with potential off-target effects on human folate metabolism. | ||||||
Sulfamethoxazole | 723-46-6 | sc-208405 sc-208405A sc-208405B sc-208405C | 10 g 25 g 50 g 100 g | $37.00 $55.00 $69.00 $109.00 | 5 | |
Sulfamethoxazole is a sulfonamide antibacterial that can disrupt folate synthesis, potentially altering MTHFD2L-related pathways. | ||||||
8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline | 90-34-6 | sc-483239 | 1 g | $360.00 | 1 | |
Primaquine is an antimalarial drug that can cause oxidative stress, possibly affecting mitochondrial proteins like MTHFD2L. | ||||||
Atovaquone | 95233-18-4 | sc-217675 | 10 mg | $270.00 | 2 | |
Atovaquone is an antimalarial that targets mitochondrial electron transport, which might influence MTHFD2L expression. | ||||||
Antimycin A | 1397-94-0 | sc-202467 sc-202467A sc-202467B sc-202467C | 5 mg 10 mg 1 g 3 g | $55.00 $63.00 $1675.00 $4692.00 | 51 | |
Antimycin A inhibits the mitochondrial electron transport chain, potentially impacting MTHFD2L expression. | ||||||